IL128882A - Retroviral vectors and libraries, and their uses - Google Patents
Retroviral vectors and libraries, and their usesInfo
- Publication number
- IL128882A IL128882A IL128882A IL12888297A IL128882A IL 128882 A IL128882 A IL 128882A IL 128882 A IL128882 A IL 128882A IL 12888297 A IL12888297 A IL 12888297A IL 128882 A IL128882 A IL 128882A
- Authority
- IL
- Israel
- Prior art keywords
- vector
- nucleic acid
- vectors
- sequences
- sequence
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims description 558
- 230000001177 retroviral effect Effects 0.000 title claims description 182
- 210000004027 cell Anatomy 0.000 claims description 428
- 108090000623 proteins and genes Proteins 0.000 claims description 393
- 239000003550 marker Substances 0.000 claims description 192
- 150000007523 nucleic acids Chemical group 0.000 claims description 189
- 230000014509 gene expression Effects 0.000 claims description 180
- 108020004414 DNA Proteins 0.000 claims description 118
- 238000004806 packaging method and process Methods 0.000 claims description 111
- 102000004169 proteins and genes Human genes 0.000 claims description 106
- 230000010076 replication Effects 0.000 claims description 102
- 102000039446 nucleic acids Human genes 0.000 claims description 99
- 108020004707 nucleic acids Proteins 0.000 claims description 99
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 94
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 90
- 241000700605 Viruses Species 0.000 claims description 87
- 230000001580 bacterial effect Effects 0.000 claims description 79
- 239000012634 fragment Substances 0.000 claims description 76
- 230000003612 virological effect Effects 0.000 claims description 70
- 230000000692 anti-sense effect Effects 0.000 claims description 62
- 239000002299 complementary DNA Substances 0.000 claims description 62
- 230000001566 pro-viral effect Effects 0.000 claims description 59
- 230000001105 regulatory effect Effects 0.000 claims description 57
- 238000011084 recovery Methods 0.000 claims description 56
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims description 53
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 51
- 230000002103 transcriptional effect Effects 0.000 claims description 51
- 108091026890 Coding region Proteins 0.000 claims description 49
- 208000015181 infectious disease Diseases 0.000 claims description 48
- 241001430294 unidentified retrovirus Species 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 43
- 229920001184 polypeptide Polymers 0.000 claims description 36
- 230000002950 deficient Effects 0.000 claims description 35
- 239000002245 particle Substances 0.000 claims description 35
- 238000013518 transcription Methods 0.000 claims description 35
- 230000035897 transcription Effects 0.000 claims description 35
- 108010091086 Recombinases Proteins 0.000 claims description 32
- 102000018120 Recombinases Human genes 0.000 claims description 32
- 102000037865 fusion proteins Human genes 0.000 claims description 31
- 108020001507 fusion proteins Proteins 0.000 claims description 31
- 230000001413 cellular effect Effects 0.000 claims description 26
- 238000010367 cloning Methods 0.000 claims description 25
- 230000010354 integration Effects 0.000 claims description 25
- 102000053642 Catalytic RNA Human genes 0.000 claims description 19
- 108090000994 Catalytic RNA Proteins 0.000 claims description 19
- 230000004568 DNA-binding Effects 0.000 claims description 19
- 230000002068 genetic effect Effects 0.000 claims description 19
- 108091092562 ribozyme Proteins 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 16
- 230000001939 inductive effect Effects 0.000 claims description 16
- 102000004190 Enzymes Human genes 0.000 claims description 15
- 108090000790 Enzymes Proteins 0.000 claims description 15
- 108010054278 Lac Repressors Proteins 0.000 claims description 14
- 230000003834 intracellular effect Effects 0.000 claims description 13
- 108010051219 Cre recombinase Proteins 0.000 claims description 12
- 230000002458 infectious effect Effects 0.000 claims description 12
- 231100000518 lethal Toxicity 0.000 claims description 12
- 230000001665 lethal effect Effects 0.000 claims description 12
- 239000013611 chromosomal DNA Substances 0.000 claims description 10
- 230000001419 dependent effect Effects 0.000 claims description 9
- 239000005090 green fluorescent protein Substances 0.000 claims description 9
- 108010067902 Peptide Library Proteins 0.000 claims description 8
- 229960000723 ampicillin Drugs 0.000 claims description 8
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 8
- 108700004025 env Genes Proteins 0.000 claims description 8
- 229930027917 kanamycin Natural products 0.000 claims description 8
- 229960000318 kanamycin Drugs 0.000 claims description 8
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 8
- 229930182823 kanamycin A Natural products 0.000 claims description 8
- 108091008146 restriction endonucleases Proteins 0.000 claims description 8
- 108010046276 FLP recombinase Proteins 0.000 claims description 7
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 7
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 7
- 229960004927 neomycin Drugs 0.000 claims description 7
- 229930193140 Neomycin Natural products 0.000 claims description 6
- 239000004098 Tetracycline Substances 0.000 claims description 5
- 108010084455 Zeocin Proteins 0.000 claims description 5
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 claims description 5
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 claims description 5
- 229960002180 tetracycline Drugs 0.000 claims description 5
- 229930101283 tetracycline Natural products 0.000 claims description 5
- 235000019364 tetracycline Nutrition 0.000 claims description 5
- 150000003522 tetracyclines Chemical class 0.000 claims description 5
- 229960005091 chloramphenicol Drugs 0.000 claims description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 4
- 108700004026 gag Genes Proteins 0.000 claims description 4
- 108010083127 phage repressor proteins Proteins 0.000 claims description 4
- 108700004029 pol Genes Proteins 0.000 claims description 4
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 claims description 4
- 108010092160 Dactinomycin Proteins 0.000 claims description 3
- 229930182566 Gentamicin Natural products 0.000 claims description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 3
- 229930182555 Penicillin Natural products 0.000 claims description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 3
- 229930183665 actinomycin Natural products 0.000 claims description 3
- 108091006047 fluorescent proteins Proteins 0.000 claims description 3
- 102000034287 fluorescent proteins Human genes 0.000 claims description 3
- 229940049954 penicillin Drugs 0.000 claims description 3
- 210000004507 artificial chromosome Anatomy 0.000 claims description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims description 2
- 229960000951 mycophenolic acid Drugs 0.000 claims description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 2
- 108091092584 GDNA Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 138
- 102000053602 DNA Human genes 0.000 description 115
- 235000018102 proteins Nutrition 0.000 description 96
- 230000006870 function Effects 0.000 description 79
- 239000013612 plasmid Substances 0.000 description 51
- 210000004962 mammalian cell Anatomy 0.000 description 50
- 238000012216 screening Methods 0.000 description 41
- 241000701822 Bovine papillomavirus Species 0.000 description 33
- 238000004519 manufacturing process Methods 0.000 description 31
- 238000003780 insertion Methods 0.000 description 28
- 230000037431 insertion Effects 0.000 description 28
- 238000001890 transfection Methods 0.000 description 28
- 239000000047 product Substances 0.000 description 27
- 238000005215 recombination Methods 0.000 description 26
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 25
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 25
- 230000006798 recombination Effects 0.000 description 25
- 238000010276 construction Methods 0.000 description 23
- 238000002955 isolation Methods 0.000 description 23
- 125000003729 nucleotide group Chemical group 0.000 description 23
- 241000701022 Cytomegalovirus Species 0.000 description 22
- 239000013604 expression vector Substances 0.000 description 22
- 239000002773 nucleotide Substances 0.000 description 22
- 238000003752 polymerase chain reaction Methods 0.000 description 22
- 230000027455 binding Effects 0.000 description 21
- 229920002477 rna polymer Polymers 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 108091034117 Oligonucleotide Proteins 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 230000003321 amplification Effects 0.000 description 18
- 238000001727 in vivo Methods 0.000 description 18
- 238000003199 nucleic acid amplification method Methods 0.000 description 18
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 17
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 17
- 230000012010 growth Effects 0.000 description 17
- 239000012528 membrane Substances 0.000 description 17
- 108020004999 messenger RNA Proteins 0.000 description 17
- 230000014616 translation Effects 0.000 description 17
- 239000013603 viral vector Substances 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 16
- 230000028327 secretion Effects 0.000 description 16
- 230000008685 targeting Effects 0.000 description 16
- 238000013519 translation Methods 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 241001631646 Papillomaviridae Species 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 150000001413 amino acids Chemical group 0.000 description 13
- 239000011324 bead Substances 0.000 description 13
- 230000008488 polyadenylation Effects 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 238000012546 transfer Methods 0.000 description 13
- 108020004635 Complementary DNA Proteins 0.000 description 12
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 12
- 101100126329 Mus musculus Islr2 gene Proteins 0.000 description 12
- 238000013459 approach Methods 0.000 description 12
- 230000004927 fusion Effects 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 108091005804 Peptidases Proteins 0.000 description 11
- 239000004365 Protease Substances 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 241000710188 Encephalomyocarditis virus Species 0.000 description 10
- 102100034349 Integrase Human genes 0.000 description 10
- 108010017842 Telomerase Proteins 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 230000030833 cell death Effects 0.000 description 10
- 239000002458 cell surface marker Substances 0.000 description 10
- 210000000349 chromosome Anatomy 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 230000029087 digestion Effects 0.000 description 10
- 238000001400 expression cloning Methods 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 238000012423 maintenance Methods 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 9
- 108010076504 Protein Sorting Signals Proteins 0.000 description 9
- 108020005091 Replication Origin Proteins 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 108060008226 thioredoxin Proteins 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 241000702421 Dependoparvovirus Species 0.000 description 8
- 101710128836 Large T antigen Proteins 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 102000002933 Thioredoxin Human genes 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000000234 capsid Anatomy 0.000 description 8
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 8
- 230000002779 inactivation Effects 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 229940094937 thioredoxin Drugs 0.000 description 8
- 101710096438 DNA-binding protein Proteins 0.000 description 7
- 101710163270 Nuclease Proteins 0.000 description 7
- 108020005067 RNA Splice Sites Proteins 0.000 description 7
- 108020004682 Single-Stranded DNA Proteins 0.000 description 7
- 238000001261 affinity purification Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000001052 transient effect Effects 0.000 description 7
- 241000701161 unidentified adenovirus Species 0.000 description 7
- 210000002845 virion Anatomy 0.000 description 7
- 108091062157 Cis-regulatory element Proteins 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
- XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 6
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 6
- 108020005038 Terminator Codon Proteins 0.000 description 6
- 108010022394 Threonine synthase Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 229960003677 chloroquine Drugs 0.000 description 6
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 102000004419 dihydrofolate reductase Human genes 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 229930182817 methionine Natural products 0.000 description 6
- 238000010606 normalization Methods 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 6
- 238000002823 phage display Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 101150003560 trfA gene Proteins 0.000 description 6
- 241001515965 unidentified phage Species 0.000 description 6
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 5
- 108010009575 CD55 Antigens Proteins 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 5
- 101710125507 Integrase/recombinase Proteins 0.000 description 5
- 101710125418 Major capsid protein Proteins 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241001045988 Neogene Species 0.000 description 5
- 102000009661 Repressor Proteins Human genes 0.000 description 5
- 241001492360 Retroviral provirus Species 0.000 description 5
- 108020005202 Viral DNA Proteins 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 5
- 210000005260 human cell Anatomy 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 5
- 101150091879 neo gene Proteins 0.000 description 5
- 229950010131 puromycin Drugs 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000003146 transient transfection Methods 0.000 description 5
- 238000001926 trapping method Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 241000271566 Aves Species 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- -1 DNA or RNA Chemical class 0.000 description 4
- 230000004543 DNA replication Effects 0.000 description 4
- 101710091045 Envelope protein Proteins 0.000 description 4
- 101710177291 Gag polyprotein Proteins 0.000 description 4
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 4
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 4
- 101001040800 Homo sapiens Integral membrane protein GPR180 Proteins 0.000 description 4
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 4
- 102100034353 Integrase Human genes 0.000 description 4
- 241000713869 Moloney murine leukemia virus Species 0.000 description 4
- 101710188315 Protein X Proteins 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 238000004873 anchoring Methods 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 108010078428 env Gene Products Proteins 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 238000011031 large-scale manufacturing process Methods 0.000 description 4
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- AUUIARVPJHGTSA-UHFFFAOYSA-N 3-(aminomethyl)chromen-2-one Chemical compound C1=CC=C2OC(=O)C(CN)=CC2=C1 AUUIARVPJHGTSA-UHFFFAOYSA-N 0.000 description 3
- 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 3
- 102100026189 Beta-galactosidase Human genes 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 101710094648 Coat protein Proteins 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 230000004544 DNA amplification Effects 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108091029865 Exogenous DNA Proteins 0.000 description 3
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 3
- 241000829111 Human polyomavirus 1 Species 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 241000709664 Picornaviridae Species 0.000 description 3
- 241000125945 Protoparvovirus Species 0.000 description 3
- 108010087512 R recombinase Proteins 0.000 description 3
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 3
- 108010052160 Site-specific recombinase Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091034131 VA RNA Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000007877 drug screening Methods 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 101150030339 env gene Proteins 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 101150066555 lacZ gene Proteins 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 101150040383 pel2 gene Proteins 0.000 description 3
- 101150050446 pelB gene Proteins 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 108060006184 phycobiliprotein Proteins 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000006152 selective media Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000003153 stable transfection Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 108010040614 terminase Proteins 0.000 description 3
- 230000005760 tumorsuppression Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 108020005065 3' Flanking Region Proteins 0.000 description 2
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 2
- 108020005029 5' Flanking Region Proteins 0.000 description 2
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 102100021975 CREB-binding protein Human genes 0.000 description 2
- 101100008638 Caenorhabditis elegans daf-1 gene Proteins 0.000 description 2
- 241000710777 Classical swine fever virus Species 0.000 description 2
- OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 2
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 101710150114 Protein rep Proteins 0.000 description 2
- 102000014450 RNA Polymerase III Human genes 0.000 description 2
- 108010078067 RNA Polymerase III Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 101710152114 Replication protein Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 101710159478 Thioredoxin-like protein Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 108091026822 U6 spliceosomal RNA Proteins 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 108091005971 Wild-type GFP Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 108010004073 cysteinylcysteine Proteins 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000010502 episomal replication Effects 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical class O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 101150098622 gag gene Proteins 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002743 insertional mutagenesis Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 101150056961 linX gene Proteins 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000004777 loss-of-function mutation Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 102000027450 oncoproteins Human genes 0.000 description 2
- 108091008819 oncoproteins Proteins 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 101150088264 pol gene Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000006862 quantum yield reaction Methods 0.000 description 2
- 239000013608 rAAV vector Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 102000037983 regulatory factors Human genes 0.000 description 2
- 108091008025 regulatory factors Proteins 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000010648 susceptibility to HIV infection Diseases 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 230000017613 viral reproduction Effects 0.000 description 2
- CSOJYIADHHNGRM-UHFFFAOYSA-N (+-)-6-(4-oxo-thiazolidin-2-yl)-hexanoic acid Natural products OC(=O)CCCCCC1NC(=O)CS1 CSOJYIADHHNGRM-UHFFFAOYSA-N 0.000 description 1
- QAGQMOJLLKQGEO-UHFFFAOYSA-N 1-aminocyclohexa-2,4-diene-1-carboxylic acid Chemical compound OC(=O)C1(N)CC=CC=C1 QAGQMOJLLKQGEO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- RCEFMOGVOYEGJN-UHFFFAOYSA-N 3-(2-hydroxyphenyl)-6-(3-nitrophenyl)-1,4-dihydropyrimidin-2-one Chemical compound OC1=CC=CC=C1N1C(=O)NC(C=2C=C(C=CC=2)[N+]([O-])=O)=CC1 RCEFMOGVOYEGJN-UHFFFAOYSA-N 0.000 description 1
- 101150113019 74 gene Proteins 0.000 description 1
- 239000013607 AAV vector Substances 0.000 description 1
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 1
- 102100033647 Activity-regulated cytoskeleton-associated protein Human genes 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 241000710189 Aphthovirus Species 0.000 description 1
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 1
- 108010002913 Asialoglycoproteins Proteins 0.000 description 1
- 241000701844 Bacillus virus phi29 Species 0.000 description 1
- 108090000363 Bacterial Luciferases Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101710186200 CCAAT/enhancer-binding protein Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 102000011683 Centromere Protein B Human genes 0.000 description 1
- 108010076305 Centromere Protein B Proteins 0.000 description 1
- 101000709520 Chlamydia trachomatis serovar L2 (strain 434/Bu / ATCC VR-902B) Atypical response regulator protein ChxR Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000388186 Deltapapillomavirus 4 Species 0.000 description 1
- 101710106383 Disulfide bond formation protein B Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 101150082674 E2 gene Proteins 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 241000713730 Equine infectious anemia virus Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 101100481527 Escherichia phage N15 gene 19 gene Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000702189 Escherichia virus Mu Species 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102220566469 GDNF family receptor alpha-1_S65T_mutation Human genes 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000945520 Gallus gallus CCAAT/enhancer-binding protein beta Proteins 0.000 description 1
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
- 108010014458 Gin recombinase Proteins 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241001182508 Gobiosoma bosc Species 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 1
- 102000000039 Heat Shock Transcription Factor Human genes 0.000 description 1
- 108050008339 Heat Shock Transcription Factor Proteins 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 101710196632 LexA repressor Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 241000588629 Moraxella lacunata Species 0.000 description 1
- 101100005318 Mus musculus Ctsr gene Proteins 0.000 description 1
- 101100473053 Mus musculus Hnrnpab gene Proteins 0.000 description 1
- 101100523604 Mus musculus Rassf5 gene Proteins 0.000 description 1
- 241000713883 Myeloproliferative sarcoma virus Species 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 101500013104 Pelophylax ridibundus Secretoneurin Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 101710116318 Probable disulfide formation protein Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 101710088839 Replication initiation protein Proteins 0.000 description 1
- 241000702632 Rice dwarf virus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 101100289792 Squirrel monkey polyomavirus large T gene Proteins 0.000 description 1
- 102000015215 Stem Cell Factor Human genes 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 241000030538 Thecla Species 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 101150100931 VI gene Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- UYRDHEJRPVSJFM-VSWVFQEASA-N [(1s,3r)-3-hydroxy-4-[(3e,5e,7e,9e,11z)-11-[4-[(e)-2-[(1r,3s,6s)-3-hydroxy-1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-6-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaenylidene]-3,5,5-trimethylcyclohexyl] acetate Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C=C\C=C(/C)\C=C/1C=C(\C=C\[C@]23[C@@](O2)(C)C[C@@H](O)CC3(C)C)C(=O)O\1 UYRDHEJRPVSJFM-VSWVFQEASA-N 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 108010041089 apoaequorin Proteins 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 101150102092 ccdB gene Proteins 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008622 extracellular signaling Effects 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000010359 gene isolation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 102000005396 glutamine synthetase Human genes 0.000 description 1
- 108020002326 glutamine synthetase Proteins 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- CEQFOVLGLXCDCX-WUKNDPDISA-N methyl red Chemical compound C1=CC(N(C)C)=CC=C1\N=N\C1=CC=CC=C1C(O)=O CEQFOVLGLXCDCX-WUKNDPDISA-N 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- UTIQDNPUHSAVDN-UHFFFAOYSA-N peridinin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC=CC=C2/OC(=O)C(=C2)C=CC34OC3(C)CC(O)CC4(C)C)C)C(C)(O)C1 UTIQDNPUHSAVDN-UHFFFAOYSA-N 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 125000005642 phosphothioate group Chemical group 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 108010094020 polyglycine Proteins 0.000 description 1
- 229920000232 polyglycine polymer Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- ZRHANBBTXQZFSP-UHFFFAOYSA-M potassium;4-amino-3,5,6-trichloropyridine-2-carboxylate Chemical compound [K+].NC1=C(Cl)C(Cl)=NC(C([O-])=O)=C1Cl ZRHANBBTXQZFSP-UHFFFAOYSA-M 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 238000002165 resonance energy transfer Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical class [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000010451 viral insertion Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/60—Vectors containing traps for, e.g. exons, promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/716,926 US6025192A (en) | 1996-09-20 | 1996-09-20 | Modified retroviral vectors |
| US08/820,931 US6255071B1 (en) | 1996-09-20 | 1997-03-19 | Mammalian viral vectors and their uses |
| PCT/US1997/017579 WO1998012339A2 (en) | 1996-09-20 | 1997-09-22 | Viral vectors and their uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL128882A0 IL128882A0 (en) | 2000-01-31 |
| IL128882A true IL128882A (en) | 2006-10-05 |
Family
ID=27109627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL128882A IL128882A (en) | 1996-09-20 | 1997-09-22 | Retroviral vectors and libraries, and their uses |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6255071B1 (enExample) |
| EP (1) | EP0932695A2 (enExample) |
| JP (1) | JP2002514054A (enExample) |
| AU (1) | AU738156B2 (enExample) |
| IL (1) | IL128882A (enExample) |
| WO (1) | WO1998012339A2 (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE344322T1 (de) | 1998-02-13 | 2006-11-15 | Koester Hubert | Verwendung von ribozymen zur bestimmung der funktion von genen |
| US7090976B2 (en) * | 1999-11-10 | 2006-08-15 | Rigel Pharmaceuticals, Inc. | Methods and compositions comprising Renilla GFP |
| DE19956568A1 (de) * | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US20010046669A1 (en) * | 1999-02-24 | 2001-11-29 | Mccobmie William R. | Genetically filtered shotgun sequencing of complex eukaryotic genomes |
| WO2000053743A1 (en) | 1999-03-12 | 2000-09-14 | Gpc Biotech, Inc. | Methods and reagents for identifying synthetic genetic elements |
| EP1165842A4 (en) * | 1999-03-16 | 2004-07-07 | Dana Farber Cancer Inst Inc | LENTIVIRAL VECTOR SYSTEM FOR LARGE QUANTITY SCREENING |
| EP1173597A1 (en) * | 1999-04-29 | 2002-01-23 | Aarhus University | Expression of heterologous genes from an ires translational cassette in retroviral vectors |
| US20050266544A1 (en) * | 1999-04-30 | 2005-12-01 | Human Gene Therapy Research Institute | Methods and compositions for increasing viral vector production in packaging cell lines |
| US7829693B2 (en) * | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| US20030084471A1 (en) | 2000-03-16 | 2003-05-01 | David Beach | Methods and compositions for RNA interference |
| US20040235173A1 (en) * | 2000-07-03 | 2004-11-25 | Gala Design, Inc. | Production of host cells containing multiple integrating vectors by serial transduction |
| US6852510B2 (en) * | 2000-07-03 | 2005-02-08 | Gala Design Inc | Host cells containing multiple integrating vectors |
| US20020106729A1 (en) * | 2000-07-03 | 2002-08-08 | Bleck Gregory T. | Expression vectors |
| US20030224415A1 (en) * | 2001-06-29 | 2003-12-04 | Gala Design, Inc. | Selection free growth of host cells containing multiple integrating vectors |
| US20030175972A1 (en) * | 2000-10-20 | 2003-09-18 | Daley George Q. | Expression vectors and uses thereof |
| AU2002215363B2 (en) * | 2000-10-25 | 2006-10-12 | Monsanto Technology Llc | Cotton event PV-GHGT07(1445) and compositions and methods for detection thereof |
| AU2002246829A1 (en) * | 2000-12-22 | 2002-07-30 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health A | Methods to control the host range of retroviral vectors |
| US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| CA2437309A1 (en) * | 2001-02-05 | 2002-08-15 | Minos Biosystems Limited | Insertional mutagenesis technique |
| US20030082140A1 (en) * | 2001-08-20 | 2003-05-01 | Fisher Paul B. | Combinatorial methods for inducing cancer cell death |
| US20030054354A1 (en) * | 2001-08-23 | 2003-03-20 | Bennett C. Frank | Use of antisense oligonucleotide libraries for identifying gene function |
| US20030050266A1 (en) * | 2001-09-07 | 2003-03-13 | Fisher Paul B. | Anti-tumor effects of prostate carcinoma tumor antigen-1 |
| US7195916B2 (en) * | 2001-09-13 | 2007-03-27 | California Institute Of Technology | Method for expression of small antiviral RNA molecules within a cell |
| ATE439041T1 (de) * | 2001-09-13 | 2009-08-15 | California Inst Of Techn | Verfahren zur expression von kleinen antiviralen rna-molekülen innerhalb einer zelle |
| US7737124B2 (en) | 2001-09-13 | 2010-06-15 | California Institute Of Technology | Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell |
| US20040038304A1 (en) * | 2002-03-28 | 2004-02-26 | Gala Design, Inc. | Antibody libraries |
| US7384738B2 (en) * | 2002-03-28 | 2008-06-10 | Bremel Robert D | Retrovirus-based genomic screening |
| EP1912069A3 (en) | 2002-06-05 | 2008-07-09 | Sopherion Therapeutics, Inc. | Method to screen ligands using eukaryotic cell display |
| WO2003104415A2 (en) * | 2002-06-05 | 2003-12-18 | Sopherion Therapeutics, Inc. | Method to screen ligands using eukaryotic cell display |
| EP3170890A1 (en) | 2002-08-21 | 2017-05-24 | Revivicor, Inc. | Porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase |
| US20040052161A1 (en) * | 2002-09-17 | 2004-03-18 | Steven Liao | Mechanical clock having wireless manipulation and adjustment function |
| US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| AU2003241409A1 (en) * | 2003-05-12 | 2005-01-21 | Potomac Pharmaceuticals, Inc. | Gene expression suppression agents |
| US20050064547A1 (en) * | 2003-09-24 | 2005-03-24 | Brown Arthur M. | Vectors and transfected cells |
| ES2411962T3 (es) | 2003-10-24 | 2013-07-09 | Gencia Corporation | Métodos y composiciones para suministrar polinucleótidos |
| US8507277B2 (en) | 2003-10-24 | 2013-08-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides |
| US8062891B2 (en) | 2003-10-24 | 2011-11-22 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to plants |
| US8133733B2 (en) | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
| US20090123468A1 (en) | 2003-10-24 | 2009-05-14 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
| US20050221429A1 (en) * | 2004-01-16 | 2005-10-06 | Cardinal Health Pts, Llc | Host cells containing multiple integrating vectors comprising an amplifiable marker |
| US8053232B2 (en) | 2004-01-23 | 2011-11-08 | Virxsys Corporation | Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing |
| EP1725112A4 (en) * | 2004-02-05 | 2007-10-24 | Massachusetts Inst Technology | CELL DISPLAY LIBRARIES |
| AU2005269527B2 (en) | 2004-07-26 | 2011-12-01 | Pfenex Inc. | Process for improved protein expression by strain engineering |
| US20080026410A1 (en) * | 2004-12-02 | 2008-01-31 | Antonia Vlahou | Biomarkers for Bladder Cancer |
| US20060183893A1 (en) * | 2005-01-25 | 2006-08-17 | North Don A | Nucleic acids for apoptosis of cancer cells |
| EP1841866B1 (en) * | 2005-01-25 | 2009-04-22 | Sky Genetics, Inc. | Nucleic acids for apoptosis of cancer cells |
| US7790446B2 (en) * | 2005-02-11 | 2010-09-07 | Kosagen Cell Factory Oü | Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products |
| US8377653B2 (en) * | 2005-02-11 | 2013-02-19 | Icosagen Cell Factory Oü | Viral expression plasmids for production of proteins, antibodies, enzymes, virus-like particles and for use in cell-based assays |
| US9085774B2 (en) | 2005-04-19 | 2015-07-21 | Basf Plant Science Gmbh | Methods controlling gene expression |
| WO2006128084A2 (en) * | 2005-05-27 | 2006-11-30 | The Trustees Of Columbia University In The City Of New York | Trps1-mediated modulation of hair growth |
| WO2006128085A2 (en) * | 2005-05-27 | 2006-11-30 | The Trustees Of Columbia University In The City Of New York | Cadherin-11-mediated modulation of hair growth |
| CA2617930A1 (en) | 2005-08-09 | 2007-03-29 | Revivicor, Inc. | Transgenic ungulates expressing ctla4-ig and uses thereof |
| CN101268194A (zh) | 2005-09-20 | 2008-09-17 | 巴斯福植物科学有限公司 | 使用ta-siRNA调控基因表达的方法 |
| US8048999B2 (en) * | 2005-12-13 | 2011-11-01 | Kyoto University | Nuclear reprogramming factor |
| US20090227032A1 (en) | 2005-12-13 | 2009-09-10 | Kyoto University | Nuclear reprogramming factor and induced pluripotent stem cells |
| US8278104B2 (en) * | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| US8129187B2 (en) * | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
| US20080045471A1 (en) * | 2006-03-27 | 2008-02-21 | North Don A | Nucleic Acids For Apoptosis Of Cancer Cells |
| US8252527B2 (en) * | 2007-02-16 | 2012-08-28 | The Research Foundation Of State University Of New York | Method for identification of polynucleotides capable of cleaving target mRNA sequences |
| EP2142651B1 (en) | 2007-04-27 | 2013-05-22 | Pfenex Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| CA2684923C (en) | 2007-05-02 | 2015-01-06 | Merial Limited | Dna plasmids having improved expression and stability |
| JP2008307007A (ja) * | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| US9213999B2 (en) * | 2007-06-15 | 2015-12-15 | Kyoto University | Providing iPSCs to a customer |
| JP5346925B2 (ja) * | 2008-05-02 | 2013-11-20 | 国立大学法人京都大学 | 核初期化方法 |
| CA2726862A1 (en) * | 2008-06-30 | 2010-01-21 | Atgcell Inc. | Mammalian cell expression vectors and utilization |
| US8450473B2 (en) | 2009-04-30 | 2013-05-28 | The Research Foundation Of State University Of New York | Compositions and methods for therapy of macular degeneration |
| US9150905B2 (en) | 2012-05-08 | 2015-10-06 | Adaptive Biotechnologies Corporation | Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions |
| EP2986635B1 (en) * | 2013-04-18 | 2018-10-03 | Fondazione Telethon | Effective delivery of large genes by dual aav vectors |
| US9708657B2 (en) | 2013-07-01 | 2017-07-18 | Adaptive Biotechnologies Corp. | Method for generating clonotype profiles using sequence tags |
| US11390921B2 (en) | 2014-04-01 | 2022-07-19 | Adaptive Biotechnologies Corporation | Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs) |
| US10066265B2 (en) | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
| EP3715455A1 (en) | 2014-10-29 | 2020-09-30 | Adaptive Biotechnologies Corp. | Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples |
| GB201603372D0 (en) * | 2016-02-26 | 2016-04-13 | Ucl Business Plc | Cell |
| US10428325B1 (en) | 2016-09-21 | 2019-10-01 | Adaptive Biotechnologies Corporation | Identification of antigen-specific B cell receptors |
| WO2018232079A1 (en) | 2017-06-14 | 2018-12-20 | Daley George Q | Hematopoietic stem and progenitor cells derived from hemogenic endothelial cells by episomal plasmid gene transfer |
| US11254980B1 (en) | 2017-11-29 | 2022-02-22 | Adaptive Biotechnologies Corporation | Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements |
| US20220243212A1 (en) * | 2019-06-21 | 2022-08-04 | Asklepios Biopharmaceutical, Inc. | Production of vectors using phage origin of replication |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1293460C (en) | 1985-10-07 | 1991-12-24 | Brian Lee Sauer | Site-specific recombination of dna in yeast |
| US5378618A (en) | 1988-04-15 | 1995-01-03 | E. I. Du Pont De Nemours And Company | Vitro headful packaging system for cloning DNA fragments as large as 95kb |
| EP0511311A4 (en) | 1990-01-19 | 1993-05-26 | United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Novel retroviral vectors |
-
1997
- 1997-03-19 US US08/820,931 patent/US6255071B1/en not_active Expired - Lifetime
- 1997-09-22 AU AU46590/97A patent/AU738156B2/en not_active Ceased
- 1997-09-22 IL IL128882A patent/IL128882A/en not_active IP Right Cessation
- 1997-09-22 JP JP51502898A patent/JP2002514054A/ja not_active Ceased
- 1997-09-22 WO PCT/US1997/017579 patent/WO1998012339A2/en not_active Ceased
- 1997-09-22 EP EP97945369A patent/EP0932695A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998012339A3 (en) | 1998-09-03 |
| AU738156B2 (en) | 2001-09-13 |
| JP2002514054A (ja) | 2002-05-14 |
| EP0932695A2 (en) | 1999-08-04 |
| WO1998012339A2 (en) | 1998-03-26 |
| AU4659097A (en) | 1998-04-14 |
| US6255071B1 (en) | 2001-07-03 |
| IL128882A0 (en) | 2000-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU738156B2 (en) | Viral vectors and their uses | |
| WO1998012339A9 (en) | Viral vectors and their uses | |
| US6025192A (en) | Modified retroviral vectors | |
| US7183395B2 (en) | Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same | |
| US20030082559A1 (en) | Methods and reagents for amplification and manipulation of vector and target nucleic acid sequences | |
| US5627058A (en) | Retrovirus promoter-trap vectors | |
| AU699706B2 (en) | Improved vectors for gene therapy | |
| EP1336652A1 (en) | Cells to be used in producing virus vector, process for producing the same and process for producing virus vector with the use of the cells | |
| WO1994024870A1 (en) | Retroviral vectors capable of expressing multimeric proteins from multiple translational initiation sites | |
| JP2002542834A (ja) | レトロウイルスベクターでのｉｒｅｓ転写カセットからの異種遺伝子群の発現 | |
| AU773277B2 (en) | Viral vectors and their uses | |
| E Tolmachov | Building mosaics of therapeutic plasmid gene vectors | |
| CA2262476C (en) | Viral vectors and their uses | |
| WO2002034929A9 (en) | Expression vectors and uses thereof | |
| JP7530881B2 (ja) | 操作されたレシーバ細胞への核酸配列のリコンビナーゼ媒介カセット交換組込み中の細胞のトレース及び操作のための細胞表面タグ交換（ｃｓｔｅ）システム | |
| AU2001231206B2 (en) | Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same | |
| US20020076688A1 (en) | Compositions and methods for the discovery and selection of biological information | |
| EP4646484A1 (en) | Methods and systems for engineering cells and for target validation | |
| US20080206873A1 (en) | Complex | |
| WO2000061809A2 (en) | Methods and nucleic acid vectors for rapid and parallel assay development, for characterization of biological response modifiers | |
| Sandrock et al. | Enhanced expression of exogenous genes from retroviruses using HIV2/Tat | |
| WO2003064659A1 (en) | Methods and compositions for optimizing recombinant expression | |
| Blø et al. | Expanding the spectrum of genetic elements transferable by retroviral vectors | |
| AU2001231206A1 (en) | Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same | |
| WO2003027260A2 (en) | Methods and compositions for generating homozygous mutations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ERR | Corrigendum |
Free format text: IN JOURNAL 7/2006 P. 2706 PATENT APPLICATION NO. 128882 CORRECT PRIORITY NUMBER TO- 08/716926 08/820931 |
|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |